Indevus (IDEV) Announces Agreement With Teva (TEVA) to Develop Pagoclone for the Treatment of Stuttering
Tweet Send to a Friend
Indevus Pharmaceuticals (Nasdaq: IDEV) announced that it has signed a development, license and commercialization agreement with Teva Pharmaceuticals (Nasdaq: TEVA) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
